Prelude Therapeutics Inc (PRLD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $275.32M
Last updated: Nov 17, 2026 at 11:05 AM ET
Prelude Therapeutics Inc (PRLD) Stock Forecast
Analysts expect Prelude Therapeutics (PRLD) to earn -$0.57 per share in the fiscal year ending Dec 31, 2026, on revenue of $38.91M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.58.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.60, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 40.0% |
| Buy | 3 | 60.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 6.6%.
- Fiscal year ending Dec 31, 2026
- -$0.57
- EPS consensus, revenue $38.91M
- Fiscal year ending Dec 31, 2027
- -$0.58
- EPS consensus, revenue $36.33M
- Next report
- Mar 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.57 | -$0.61 to -$0.54 | 4 | $38.91M | $20.28M to $110.30M | 5 |
| Dec 31, 2027 | -$0.58 | -$0.79 to -$0.11 | 4 | $36.33M | $12.00M to $100.00M | 4 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.17 | -$0.22 to -$0.15 | 6 | $4.00M | N/A | 6 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.85.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.57 | -$0.58 | -$0.54 | -$0.54 | -$0.85 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.58 | -$0.55 | -$0.75 | -$0.75 | -$0.94 | N/A |
Frequently Asked Questions About PRLD
What is the PRLD stock forecast?
Consensus analyst estimates put Prelude Therapeutics's EPS at -$0.57 for the fiscal year ending Dec 31, 2026, on revenue of $38.91M. The consensus rating from 5 analysts is Buy.
How do analysts rate PRLD stock?
Of 5 analysts covering Prelude Therapeutics, 2 rate it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PRLD next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.57, with estimates from -$0.61 to -$0.54 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.58, with estimates from -$0.79 to -$0.11 from 4 analysts.
What revenue do analysts expect from Prelude Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $38.91M, with estimates from $20.28M to $110.30M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $36.33M, with estimates from $12.00M to $100.00M.
How many analysts cover PRLD?
5 analysts rate Prelude Therapeutics stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PRLD pages: Overview, Earnings, Forecast, Financials, Competitors